Agalsidase Beta: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Agalsidase Beta. Educational only — not medical advice.
Labeled uses
FABRAZYME® is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.
Source: FDA labeling via NIH DailyMed (set 988513ab…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.